Citations

Mayo Clinic

Showing 10 of 108551 citations.

Development of a Near-Field Sensor for Diagnosis of Liver Diseases Using 3D-EM Simulation of Mouse Model
Samaddar, Poulami , Gaddam, Sunil , Rahman, Md Mirazur , Mitra, Dipankar , Arunachalam, S P , Dey, Shuvashis , Roy, Sayan , Arunachalam, Shivaram P.

2023 IEEE Microwaves, Antennas, and Propagation Conference (MAPCON) | March 20, 2024 | Volume: No volume available | Issue: No issue available | Pages: 1-4

10.1109/mapcon58678.2023.10463714 Get It

Use of crushed tranexamic acid tablets in water for paediatric patients with bleeding disorders
Al‐Huniti, Ahmad , Marshall, Linda, Rusk, Dawn, Pruthi, Rajiv K. , Rodriguez, Vilmarie , Ferdjallah, Asmaa , Kuhn, Alexis

Haemophilia | March 20, 2024 | Volume: 30 | Issue: 3 | Pages: 648-657

10.1111/hae.14996 | PMID 38507239 Get It

AbstractBackgroundΕ‐Aminocaproic acid oral solution (EACA OS) is the only commercially available antifibrinolytic for patients who cannot swallow tablets. Insurance denials and high costs remain barriers to its use.ObjectivesTo determine the safety and efficacy of crushed tranexamic acid tablets in water (cTXAw) for children with bleeding disorders.MethodsWe retrospectively reviewed records of children (<10 years) with bleeding disorders who received cTXAw or EACA OS from 1 December 2018, through 31 July 2022, at Mayo Clinic (Rochester, Minnesota). Bleeding outcomes were defined according to ISTH criteria.ResultsThirty‐two patients were included (median age, 3 years; male, n = 23). Diagnoses were VWD (n = 17), haemophilia (n = 5), FVII deficiency (n = 3), inherited platelet disorder (n = 4), ITP (n = 2), and combined FV and FVII deficiencies (n = 1). Thirty‐two courses of cTXAw (monotherapy 24/32; mean duration 6 days) and fifteen courses of EACA (monotherapy 12/15; mean duration 5 days) were administered. No surgical procedures (n = 28) were complicated by bleeding. Of the 19 bleeding events, 16 had effective haemostasis, two had no reported outcome, and one had no response. cTXAw and EACA were equally effective in preventing and treating bleeding (p value > .1). No patients had adverse effects. Eight of 19 patients (42%) who were initially prescribed EACA OS did not receive it because of cost or insurance denial.The estimated average wholesale price of one treatment was $94 for cTXAw and $905 for EACA OS.ConclusionsCTXAw appears to be an effective, safe, and low‐cost alternative option to EACA OS for young children with bleeding disorders.
Response to Comment on Pataky et al. Divergent Skeletal Muscle Metabolomic Signatures of Different Exercise Training Modes Independently Predict Cardiometabolic Risk Factors. Diabetes 2024;73:23–37
Nair, K. Sreekumaran , Pataky, Mark W , Nair, K Sreekumaran

Diabetes | March 20, 2024 | Volume: 73 | Issue: 6 | Pages: e4-e5

10.2337/dbi24-0017 | PMID 38506957 Get It

The Effect of Chronic Altitude Exposure on Chronic Obstructive Pulmonary Disease Outcomes in the SPIROMICS Cohort: An Observational Cohort Study
Suri, Rajat , Markovic, Daniela , Woo, Han, Arjomandi, Mehrdad , Bowler, Russell P. , Criner, Gerard J. , Curtis, Jeffrey L. , Dransfield, Mark T. , Fortis, Spyridon , Hoffman, Eric A. , Kaufman, Joel D. , Ortega, Victor E. , Paine, Robert, Soler, Xavier , Woodruff, Prescott G. , Hansel, Nadia N. , Cooper, Christopher B. , Bowler, Russell P , Criner, Gerard , Curtis, Jeffrey L , Dransfield, Mark T , Drummond, M Bradley , Fortis, Spyridon , Han, MeiLan King , Hoffman, Eric A , Kaner, Robert J. , Kaufman, Joel D , Krishnan, Jerry A , Martinez, Fernando , Ohar, Jill , Woodruff, Prescott G , Hansel, Nadia N , Cooper, Christopher B , Tashkin, Donald , Buhr, Russell G , Barjaktarevic, Igor , Barr, R. Graham , Drummond, Michael , Martínez, Fernando J. , Tashkin, Donald P. , Buhr, Russell G. , Barjaktarević, Igor

American Journal of Respiratory and Critical Care Medicine | March 20, 2024 | Volume: 210 | Issue: 10 | Pages: 1210-1218

10.1164/rccm.202310-1965oc | PMID 38507607 Get It

Abstract Rationale Individuals with chronic obstructive pulmonary disease (COPD) have airflow obstruction and maldistribution of ventilation. For those living at high altitude, any gas exchange abnormality is compounded by reduced partial pressures of inspired oxygen. Objectives Does residence at higher altitude exposure affect COPD outcomes, including lung function, imaging characteristics, symptoms, health status, functional exercise capacity, exacerbations, and mortality? Methods From the SPIROMICS (Subpopulation and Intermediate Outcome Measures in COPD Study) cohort, we identified individuals with COPD living below 1,000 ft (305 m) elevation (n = 1,367) versus above 4,000 ft (1,219 m) elevation (n = 288). Multivariable regression models were used to evaluate associations of exposure to high altitude with COPD-related outcomes. Measurements and Main Results Living at higher altitude was associated with reduced functional exercise capacity as defined by 6-minute-walk distance (−32.3 m [95% confidence interval, −49.8 to −14.8 m]). There were no differences in patient-reported outcomes as defined by symptoms (COPD Assessment Test and modified Medical Research Council dyspnea scale), or health status (St. George’s Respiratory Questionnaire). Higher altitude was not associated with a different rate of FEV1 decline. Higher altitude was associated with lower odds of severe exacerbations (incidence rate ratio, 0.65 [95% confidence interval, 0.46 to 0.90]). There were no differences in small airway disease, air trapping, or emphysema. In longitudinal analyses, higher altitude was associated with increased mortality (hazard ratio, 1.25 [95% confidence interval, 1.0 to 1.55]); however, this association was no longer significant when accounting for air pollution. Conclusions Long-term altitude exposure is associated with reduced functional exercise capacity in individuals with COPD, but this did not translate into differences in symptoms or health status. In addition, long-term high-altitude exposure did not affect progression of disease as defined by longitudinal changes in spirometry. Clinical trial registered with www.clinicaltrials.gov (NCT 01969344).
Skin Biopsy Detection of Phosphorylated α-Synuclein in Patients With Synucleinopathies
Levine, Todd, Bellaire, Bailey, Wang, Ningshan , Stohl, Jade, Aldridge, Georgina M. , Barboi, Alexandru , Evidente, Virgilio Gerald H. , Geschwind, Michael D. , Gil, Ramon, Gudesblatt, Mark , Khemani, Pravin , Liu, Andy , McFarland, Nikolaus R. , Miglis, Mitchell G. , Reynolds, Adam , Sahagian, Gregory , Saint-Hillaire, Marie-Helene, Schwartzbard, Julie, Yerstein, Oleg , Kaufmann, Horacio , Miglis, Mitchell G , McFarland, Nikolaus R , Gibbons, Christopher H. , Adler, Charles H. , Galasko, Douglas , González-Duarte, Alejandra , Isaacson, Stuart , Kumar, Rajeev , Lamotte, Guillaume , Reynolds, Adam, Singer, Wolfgang , Soileau, Michael J , Vernino, Steven , Freeman, Roy L. , Liu, Andy

JAMA | March 20, 2024 | Volume: 331 | Issue: 15 | Pages: 1298

10.1001/jama.2024.0792 | PMID 38506839 Get It

ImportanceFinding a reliable diagnostic biomarker for the disorders collectively known as synucleinopathies (Parkinson disease [PD], dementia with Lewy bodies [DLB], multiple system atrophy [MSA], and pure autonomic failure [PAF]) is an urgent unmet need. Immunohistochemical detection of cutaneous phosphorylated α-synuclein may be a sensitive and specific clinical test for the diagnosis of synucleinopathies.ObjectiveTo evaluate the positivity rate of cutaneous α-synuclein deposition in patients with PD, DLB, MSA, and PAF.Design, Setting, and ParticipantsThis blinded, 30-site, cross-sectional study of academic and community-based neurology practices conducted from February 2021 through March 2023 included patients aged 40 to 99 years with a clinical diagnosis of PD, DLB, MSA, or PAF based on clinical consensus criteria and confirmed by an expert review panel and control participants aged 40 to 99 years with no history of examination findings or symptoms suggestive of a synucleinopathy or neurodegenerative disease. All participants completed detailed neurologic examinations and disease-specific questionnaires and underwent skin biopsy for detection of phosphorylated α-synuclein. An expert review panel blinded to pathologic data determined the final participant diagnosis.ExposureSkin biopsy for detection of phosphorylated α-synuclein.Main OutcomesRates of detection of cutaneous α-synuclein in patients with PD, MSA, DLB, and PAF and controls without synucleinopathy.ResultsOf 428 enrolled participants, 343 were included in the primary analysis (mean [SD] age, 69.5 [9.1] years; 175 [51.0%] male); 223 met the consensus criteria for a synucleinopathy and 120 met criteria as controls after expert panel review. The proportions of individuals with cutaneous phosphorylated α-synuclein detected by skin biopsy were 92.7% (89 of 96) with PD, 98.2% (54 of 55) with MSA, 96.0% (48 of 50) with DLB, and 100% (22 of 22) with PAF; 3.3% (4 of 120) of controls had cutaneous phosphorylated α-synuclein detected.Conclusions and RelevanceIn this cross-sectional study, a high proportion of individuals meeting clinical consensus criteria for PD, DLB, MSA, and PAF had phosphorylated α-synuclein detected by skin biopsy. Further research is needed in unselected clinical populations to externally validate the findings and fully characterize the potential role of skin biopsy detection of phosphorylated α-synuclein in clinical care.
Remote Patient Monitoring to Transform Management of Febrile Neutropenia in Cancer Patients
Haddad, Tufia C. , Pritchett, Joshua C. , Paludo, Jonas , Borah, Bijan J.

NEJM Catalyst | March 20, 2024 | Volume: 5 | Issue: 4 | Pages: No page available

10.1056/cat.23.0365 Get It

Racial disparities in the utilization of invasive neuromodulation devices for the treatment of drug‐resistant focal epilepsy
Alcalá-Zermeño, Juan Luis , Fureman, Brandy , Grzeskowiak, Caitlin L. , Potnis, Ojas , Taveras, Maria, Logan, Margaret W. , Rybacki, Delanie, Friedman, Daniel , Lowenstein, Daniel H. , investigators, the HEP2, Lowenstein, Daniel , Kuzniecky, Ruben , French, Jacqueline , Grzeskowiak, Caitlin L , Taveras, Maria, French, Jacqueline A. , investigators, the HEP2

Epilepsia | March 20, 2024 | Volume: 65 | Issue: 5 | Pages: No page available

10.1111/epi.17961 | PMID 38506370 Get It

AbstractRacial disparities affect multiple dimensions of epilepsy care including epilepsy surgery. This study aims to further explore these disparities by determining the utilization of invasive neuromodulation devices according to race and ethnicity in a multicenter study of patients living with focal drug‐resistant epilepsy (DRE). We performed a post hoc analysis of the Human Epilepsy Project 2 (HEP2) data. HEP2 is a prospective study of patients living with focal DRE involving 10 sites distributed across the United States. There were no statistical differences in the racial distribution of the study population compared to the US population using census data except for patients reporting more than one race. Of 154 patients enrolled in HEP2, 55 (36%) underwent invasive neuromodulation for DRE management at some point in the course of their epilepsy. Of those, 36 (71%) were patients who identified as White. Patients were significantly less likely to have a device if they identified solely as Black/African American than if they did not (odds ratio = .21, 95% confidence interval = .05–.96, p = .03). Invasive neuromodulation for management of DRE is underutilized in the Black/African American population, indicating a new facet of racial disparities in epilepsy care.
MADD regulates natural killer cell degranulation through Rab27a activation
Medlyn, Michael J. , Maeder, E. , Bradley, Claire , Phatarpekar, Prasad V., Ham, Hyoungjun , Billadeau, Daniel D. , Maeder, Easton , Phatarpekar, Prasad, Bradley, Claire

Journal of Cell Science | March 20, 2024 | Volume: 137 | Issue: 7 | Pages: No page available

10.1242/jcs.261582 | PMID 38506245 Get It

ABSTRACT Natural killer (NK) cells have the ability to lyse other cells through the release of lytic granules (LGs). This is in part mediated by the small GTPase Rab27a, which was first identified to play a crucial role in degranulation through the study of individuals harboring mutations in the gene encoding Rab27a. However, the guanine nucleotide exchange factor (GEF) regulating the activation of Rab27a in cytotoxic lymphocytes was unknown. Here, we show that knockout of MADD significantly decreased the levels of GTP-bound Rab27a in both resting and stimulated NK cells, and MADD-deficient NK cells and CD8+ T cells displayed severely reduced degranulation and cytolytic ability, similar to that seen with Rab27a deficiency. Although MADD colocalized with Rab27a on LGs and was enriched at the cytolytic synapse, the loss of MADD did not impact Rab27a association with LGs nor their recruitment to the cytolytic synapse. Together, our results demonstrate an important role for MADD in cytotoxic lymphocyte killing.
Effect of palatine tonsil tumor resection on postoperative velopharyngeal insufficiency in transoral surgery
Wistermayer, Paul R. , Brown, Adam E. , Cave, Taylor B., Hinni, Michael L., Hayden, Richard E. , Klusovsky, Laura E., McGary, Alyssa , Nagel, Thomas H. , Chang, Brent A.

Head & Neck | March 20, 2024 | Volume: 46 | Issue: 5 | Pages: 1178-1188

10.1002/hed.27741 | PMID 38506149 Get It

AbstractBackgroundVelopharyngeal insufficiency (VPI) is a known complication of transoral surgery (TOS) for oropharyngeal HPV‐mediated squamous cell carcinoma. Controversy exists regarding adequate resection margins for balancing functional and oncologic outcomes.MethodsThis retrospective study was exempted by the IRB. Patients who underwent TOS from January 2017 to October 2022 were included. Patient characteristics, treatment details, and oncologic and functional outcomes were evaluated.ResultsFifty‐five patients were included. Mean and median follow‐up was 34 months. 98% of patients were AJCC stage I/II. Recurrence‐free survival was 96% with no local recurrences.Univariate analysis demonstrated an association between VPI and pT stage (p = 0.035), medial pterygoid resection (p = 0.049), and palatal attachment sacrifice (p < 0.001). Multivariate analysis showed sacrifice of the palatal attachments remained a significant risk for VPI (p = 0.009).ConclusionLoss of soft palate pharyngeal attachments is an independent risk factor for VPI. When oncologically appropriate, the palatal attachments to the pharynx may be preserved.
Zebrafish as a Model for Cardiovascular and Metabolic Disease: The Future of Precision Medicine
Angom, Ramcharan Singh , Nakka, Naga Malleswara Rao , Singh Angom, Ramcharan

Biomedicines | March 20, 2024 | Volume: 12 | Issue: 3 | Pages: 693

10.3390/biomedicines12030693 | PMID 38540306 Get It

The zebrafish (Danio rerio) has emerged as an appreciated and versatile model organism for studying cardiovascular and metabolic diseases, offering unique advantages for both basic research and drug discovery. The genetic conservation between zebrafish and humans and their high fecundity and transparent embryos allow for efficient large-scale genetic and drug-oriented screening studies. Zebrafish possess a simplified cardiovascular system that shares similarities with mammals, making them particularly suitable for modeling various aspects of heart development, function, and disease. The transparency of zebrafish embryos enables the real-time visualization of cardiovascular dynamics, offering insights into early embryonic events and facilitating the study of heart-related anomalies. In metabolic research, zebrafish provide a cost-effective platform for modeling obesity, type 2 diabetes, hyperlipidemia, and other metabolic disorders. Their high reproductive rate allows for the generation of large cohorts for robust statistical analyses, while advanced genetic tools, such as CRISPR/Cas9, enable precise gene editing with which to model specific genetic mutations associated with human diseases. Zebrafish metabolic models have been instrumental in elucidating the molecular mechanisms underlying metabolic diseases, studying the effects of environmental factors, and identifying potential therapeutic targets. Additionally, the permeability of zebrafish embryos to small molecules facilitates drug discovery and screening, offering a rapid and economical approach to identifying compounds with therapeutic potential. In conclusion, zebrafish cardiovascular and metabolic disease models continue to contribute significantly to our perception of disease pathogenesis, providing a platform for translational research and developing novel therapeutic interventions. The versatility, scalability, and genetic manipulability of zebrafish position them as an invaluable asset in unraveling the complexities of cardiovascular and metabolic diseases. This review presents an overview of the zebrafish model’s key features and contributions to investigating cardiovascular and metabolic disorders. We discuss the benefits and drawbacks of using zebrafish models to study human disease and the critical findings revealed by the progress in this endeavor to date.